Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer
Clinical trial NCT05606263 · UNKNOWN
Trial details
- NCT number
- NCT05606263
- Sponsor
- Xi'an Jiaotong University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2023-11-30
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.